BioSpace News Archive

Vaxcyte, Inc., a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, announced the pricing of an underwritten public offering of common stock and pre-funded warrants.

Oncopeptides AB announces that the data from the randomized head-to-head phase 3 OCEAN study, evaluating the efficacy and safety of melflufen plus dexamethasone versus pomalidomide plus dexamethasone in lenalidomide refractory patients with relapsed refractory multiple myeloma that have received 2-4 prior lines of therapy, have been published in the Lancet Hematology.

Akoya Biosciences, Inc., (Nasdaq: AKYA), The Spatial Biology Company®, today announced the commercial availability of the PhenoCycler™-Fusion system, setting a new standard in spatial biology for high-speed imaging of whole slides, at single-cell and sub-cellular resolution.

Rubius Therapeutics, Inc. today announced that the first patient has been dosed in its Phase 1/2 clinical trial of RTX-224 for the treatment of patients with certain relapsed/refractory or locally advanced solid tumors.

aTyr Pharma, Inc. today announced that the United States Adopted Names (USAN) Council and the World Health Organization’s (WHO) International Nonproprietary Name (INN) Expert Committee have selected the nonproprietary name efzofitimod for ATYR1923.

SynerFuse, Inc., a Minneapolis-based medical device company, is pleased to announce the first implantation in the company’s proof-of-concept study.

Mentor Worldwide LLC, the number one global brand in breast aesthetics, and part of the Johnson & Johnson Medical Devices Companies** today announced that the U.S. Food and Drug Administration (FDA) approved the MENTOR® MemoryGel BOOST™ Breast Implant for breast augmentation in women at least 22 years old, and for women of all ages undergoing breast reconstruction.

PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the launch of the company’s 2022 Talent Pipeline Program, a one-year, global initiative designed to provide recent college graduates with high-quality, real-world opportunities at work.

Biognosys, a leader in next-generation proteomics solutions for drug discovery and development, announced that it has obtained Good Laboratory Practice certification from Swiss health authorities for preclinical studies.

Net sales for the three months ended November 30, 2021 were $4.6 million as compared to net sales of $1.4 million for the same three months in fiscal 2021, an increase of $3.2 million, or 239%.